155 related articles for article (PubMed ID: 15272064)
1. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis.
Wade MM; Zhang Y
J Med Microbiol; 2004 Aug; 53(Pt 8):769-773. PubMed ID: 15272064
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the antituberculosis activity of weak acids by inhibitors of energy metabolism but not by anaerobiosis suggests that weak acids act differently from the front-line tuberculosis drug pyrazinamide.
Gu P; Constantino L; Zhang Y
J Med Microbiol; 2008 Sep; 57(Pt 9):1129-1134. PubMed ID: 18719183
[TBL] [Abstract][Full Text] [Related]
3. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Permar S; Sun Z
J Med Microbiol; 2002 Jan; 51(1):42-49. PubMed ID: 11800471
[TBL] [Abstract][Full Text] [Related]
4. Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis.
Huang Q; Chen ZF; Li YY; Zhang Y; Ren Y; Fu Z; Xu SQ
Chemotherapy; 2007; 53(5):338-43. PubMed ID: 17785970
[TBL] [Abstract][Full Text] [Related]
5. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide.
Zhang Y; Scorpio A; Nikaido H; Sun Z
J Bacteriol; 1999 Apr; 181(7):2044-9. PubMed ID: 10094680
[TBL] [Abstract][Full Text] [Related]
6. [Nutrient starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis].
Chen ZF; Huang Q; Li YY; Zhang Y; Ren Y; Li KS; Fu ZJ; Xu SQ
Zhonghua Jie He He Hu Xi Za Zhi; 2007 May; 30(5):359-62. PubMed ID: 17651643
[TBL] [Abstract][Full Text] [Related]
7. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.
Zimhony O; Cox JS; Welch JT; Vilchèze C; Jacobs WR
Nat Med; 2000 Sep; 6(9):1043-7. PubMed ID: 10973326
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.
Raynaud C; Lanéelle MA; Senaratne RH; Draper P; Lanéelle G; Daffé M
Microbiology (Reading); 1999 Jun; 145 ( Pt 6)():1359-1367. PubMed ID: 10411262
[TBL] [Abstract][Full Text] [Related]
9. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in Mycobacteria.
Singh P; Mishra AK; Malonia SK; Chauhan DS; Sharma VD; Venkatesan K; Katoch VM
J Commun Dis; 2006 Mar; 38(3):288-98. PubMed ID: 17373362
[TBL] [Abstract][Full Text] [Related]
10. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis.
Ahmad Z; Tyagi S; Minkowsk A; Almeida D; Nuermberger EL; Peck KM; Welch JT; Baughn AS; Jacobs WR; Grosset JH
Indian J Med Res; 2012 Nov; 136(5):808-14. PubMed ID: 23287128
[TBL] [Abstract][Full Text] [Related]
11. Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.
Speirs RJ; Welch JT; Cynamon MH
Antimicrob Agents Chemother; 1995 Jun; 39(6):1269-71. PubMed ID: 7574514
[TBL] [Abstract][Full Text] [Related]
12. Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide.
Dillon NA; Peterson ND; Rosen BC; Baughn AD
Antimicrob Agents Chemother; 2014 Dec; 58(12):7258-63. PubMed ID: 25246400
[TBL] [Abstract][Full Text] [Related]
13. A new approach for pyrazinamide susceptibility testing in Mycobacterium tuberculosis.
Zimic M; Loli S; Gilman RH; Gutierrez A; Fuentes P; Cotrina M; Kirwan D; Sheen P
Microb Drug Resist; 2012 Aug; 18(4):372-5. PubMed ID: 22372927
[TBL] [Abstract][Full Text] [Related]
14. Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
Njire M; Wang N; Wang B; Tan Y; Cai X; Liu Y; Mugweru J; Guo J; Hameed HMA; Tan S; Liu J; Yew WW; Nuermberger E; Lamichhane G; Liu J; Zhang T
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438933
[TBL] [Abstract][Full Text] [Related]
15. Long-Chain Fatty Acyl Coenzyme A Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
Rosen BC; Dillon NA; Peterson ND; Minato Y; Baughn AD
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855077
[TBL] [Abstract][Full Text] [Related]
16. The effect of growth rate on pyrazinamide activity in Mycobacterium tuberculosis - insights for early bactericidal activity?
Pullan ST; Allnutt JC; Devine R; Hatch KA; Jeeves RE; Hendon-Dunn CL; Marsh PD; Bacon J
BMC Infect Dis; 2016 May; 16():205. PubMed ID: 27184366
[TBL] [Abstract][Full Text] [Related]
17. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.
Hu Y; Coates AR; Mitchison DA
Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713
[TBL] [Abstract][Full Text] [Related]
18. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid.
Zhang Y; Wade MM; Scorpio A; Zhang H; Sun Z
J Antimicrob Chemother; 2003 Nov; 52(5):790-5. PubMed ID: 14563891
[TBL] [Abstract][Full Text] [Related]
19. Rapid colorimetric pyrazinamide susceptibility testing of Mycobacterium tuberculosis.
Li H; Zhou LP; Luo J; Yu JP; Yang H; Wei HP
Int J Tuberc Lung Dis; 2016 Apr; 20(4):462-7. PubMed ID: 26970154
[TBL] [Abstract][Full Text] [Related]
20. In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1.
Gopal P; Tasneen R; Yee M; Lanoix JP; Sarathy J; Rasic G; Li L; Dartois V; Nuermberger E; Dick T
ACS Infect Dis; 2017 Jul; 3(7):492-501. PubMed ID: 28271875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
